Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QuidelOrtho Corporation (Nasdaq: QDEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an issuer in the in vitro diagnostics and medical device manufacturing space, QuidelOrtho uses these filings to report on its financial condition, capital structure, material agreements and other significant events.
Investors can review current reports on Form 8‑K, where QuidelOrtho furnishes press releases announcing quarterly financial results, earnings conference calls and stockholder letters discussing recent performance and strategic priorities. For example, 8‑K filings in November 2025 reference third‑quarter results and a stockholder communication, while an August 21, 2025 8‑K details a Credit Agreement that established senior secured term loan A and term loan B facilities and a revolving credit facility with a syndicate of lenders.
Alongside 8‑Ks, users can also access annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide more comprehensive information on QuidelOrtho’s business, including its diagnostic segments in clinical chemistry, immunoassay, immunohematology and molecular testing. These reports typically include discussions of risk factors, research and development spending, and other elements that shape the company’s long‑term outlook.
For those interested in governance and ownership, proxy statements and beneficial ownership reports (such as Forms 3, 4 and 5) can be used to analyze executive and director holdings and transactions, although specific examples are not detailed here. Together, these documents form a record of how QuidelOrtho communicates with regulators and investors about its operations and capital decisions.
Stock Titan enhances this information by pairing real‑time EDGAR updates with AI‑powered summaries that explain the key points of long filings in plain language. Users can quickly see what each new 10‑K, 10‑Q, 8‑K or Form 4 means for QuidelOrtho without reading every page, while still having direct access to the full text for deeper review.
QuidelOrtho Corporation’s Chief Operations Officer Philip D. McLellan reported routine equity compensation activity. On January 29, 2026, 4,897 restricted stock units vested and converted into an equal number of common shares at $0 per share. To cover tax withholding on this release, 2,017 common shares were withheld at $27.41 per share, leaving McLellan with 16,184 common shares held directly. After this vesting, he also holds 9,796 restricted stock units, scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corp’s Chief Legal Officer, Michelle A. Hodges, reported equity award activity involving restricted stock units and common shares. On January 29, 2026, 7,836 restricted stock units converted into 7,836 shares of common stock at $0, reflecting the vesting of a prior award.
To cover tax withholding on this release, 3,072 common shares were withheld at a price of $27.41 per share. After these transactions, Hodges directly owned 37,360 shares of QuidelOrtho common stock and 15,673 restricted stock units, each representing the right to receive one share if and when it vests.
QuidelOrtho Corporation’s Chief Human Resources Officer, Ronald Lee Bowman, reported the vesting of 2,938 restricted stock units on January 29, 2026, which converted into the same number of common shares at $0 per share. Following this, 1,210 shares were surrendered at $27.41 per share to cover tax withholding obligations.
After these transactions, Bowman directly owned 3,375 shares of QuidelOrtho common stock. He also continued to hold 5,878 restricted stock units, which are scheduled to vest in equal installments on January 29, 2027 and January 29, 2028, each unit representing one share of common stock.
QuidelOrtho Corporation’s Chief Financial Officer Joseph M. Busky reported routine equity compensation activity. On January 29, 2026, 8,425 restricted stock units vested, converting into the same number of shares of common stock at $0 per share. To cover related tax withholding, 2,602 shares were withheld at $27.41 per share rather than sold in the open market.
After these transactions, Busky directly holds 37,250 shares of QuidelOrtho common stock and 16,851 restricted stock units. An additional 6,920 shares are held indirectly by a trust. The remaining RSUs are scheduled to vest in equal portions in 2027 and 2028.
QuidelOrtho Corp President and CEO Brian J. Blaser reported equity compensation activity tied to restricted stock units. On January 29, 2026, 21,446 restricted stock units vested, resulting in an acquisition of 21,446 shares of common stock at $0 per share.
To cover tax withholding on this vesting, 7,755 common shares were withheld by the issuer at $27.41 per share. After these transactions, Blaser directly beneficially owned 25,142 common shares and indirectly held 29,533 shares through a trust. The filing also notes 42,892 restricted stock units remain unvested, scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corp (QDEL)11/25/2025, he exercised 7,021 non-qualified stock options at an exercise price of $15.74 per share, receiving the same number of common shares. On the same date, he sold 4,026 shares of common stock at a weighted average price of $27.8106 per share, with individual sale prices ranging from $27.81 to $27.83. Following these transactions, he directly beneficially owned 37,061 shares of QuidelOrtho common stock.
QuidelOrtho Corp (QDEL) filed a Form 4 reporting that its Chief Financial Officer, Joseph M. Busky, acquired company stock. On 11/24/2025, a trust for his benefit purchased 4,770 shares of QuidelOrtho common stock at a price of $26.0598 per share in an open-market transaction coded as a purchase. Following this trade, he beneficially owns 6,920 shares indirectly through the trust and 31,427 shares directly.
QuidelOrtho Corp (QDEL) director Mary Lake Polan reported an open-market purchase of company stock. On 11/21/2025, she bought 1,000 shares of common stock at a price of $22.43 per share in a transaction coded "P" for purchase. After this trade, she beneficially owns 12,640 shares directly and 17,353 shares indirectly through an LLC. The filing is a Form 4, which discloses changes in insider ownership.
QuidelOrtho Corporation reported insider equity activity for its Chief Legal Officer, Michelle A. Hodges. On November 18, 2025, 5,349 restricted stock units converted into the same number of common shares at $0 per share. On the same date, 2,717 common shares were disposed of at $21.28 per share to cover tax withholding obligations related to this vesting.
After these transactions, Hodges beneficially owned 32,035 shares of QuidelOrtho common stock directly and held 10,698 restricted stock units. Of these units, 5,349 shares vested on November 18, 2025 and the remaining 10,698 are scheduled to vest in equal installments on November 18, 2026 and November 18, 2027.
QuidelOrtho Corp (QDEL) reported an insider share purchase by its President and CEO, Brian J. Blaser. On 11/19/2025, he purchased 23,500 shares of common stock at a weighted average price of $21.3437 per share, with individual trade prices ranging from $20.91 to $21.72. After this transaction, he beneficially owned 29,533 shares indirectly through a trust and 11,451 shares directly. He also undertook to provide, upon request, detailed breakdowns of the number of shares purchased at each separate price.